New drug cocktail aims to beat back tough leukemia

NCT ID NCT03629171

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining two drugs—CPX-351 (a chemotherapy) and venetoclax (a targeted therapy)—can help people with acute myeloid leukemia (AML) that has come back or not responded to prior treatment. About 52 adults will take part at MD Anderson Cancer Center. The goal is to see if this combo can achieve remission and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX-351 (a liposomal combination of two chemotherapy drugs, daunorubicin and cytarabine) and venetoclax (a targeted drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with AML that has come back or not responded to other therapies.
What could go wrong: This is a small, early-phase (Phase II) trial, so results may not apply broadly. Side effects from chemotherapy and venetoclax can be serious, including infection and bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.